Defining the Minimal Important Difference in International Prostate Symptom Score for Men with Lower Urinary Tract Symptoms Using a Patient-centered Anchor Measure.

ABSTRACT:

Background and objective

Few studies have investigated the minimal important difference (MID) for the International Prostate Symptom Score (IPSS), which is essential for interpreting clinical outcomes after treatment for lower urinary tract symptoms (LUTS). The aim of our study was to determine the IPSS MID using data from a randomized controlled trial (RCT) evaluating an app-based intervention (Kranus Lutera) for LUTS in men.

Methods

Patients with LUTS diagnosed with benign prostatic hyperplasia, overactive bladder, or both by office-based urologists across Germany were included. After following the Kranus Lutera app for LUT therapy for 12 wk, participants completed the IPSS and the Patient Global Impression of Change (PGIC) questionnaire. The MID, defined as the mean chang

SUBMITTER: Wiemer L 

PROVIDER: S-EPMC12509103 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature